PDF herunterladen
CC BY-NC-ND 4.0 · AJP Rep 2019; 09(04): e353-e356
DOI: 10.1055/s-0039-3400316
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antenatal Magnesium Sulfate Exposure and Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants

Amna Qasim 
1   Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas
,
Sunil K. Jain
2   Division of Neonatology, University of Texas Medical Branch, Galveston, Texas
,
Ashraf M. Aly
3   Division of Pediatric Cardiology, University of Texas Medical Branch, Galveston, Texas
› Institutsangaben Funding Details No funding or sponsorship was involved in the production of this manuscript.
Weitere Informationen

Publikationsverlauf

06. Juni 2019

02. Juli 2019

Publikationsdatum:
14. November 2019 (online)

   Lizenzen und Reprints

Abstract

Objective The use of antenatal magnesium sulfate (MgSO4) has been associated with neuroprotective effects. One of its' proposed mechanisms of action includes antagonism of calcium channels. Calcium influx is important for closure of ductus arteriosus. We hypothesized that antenatal MgSO4 exposure may be associated with an increased risk of hemodynamically significant patent ductus arteriosus (HsPDA) in premature infants (PI).

Study Design A prospective cohort study conducted in two parts. PI (< 32 weeks and < 1,500 g) were recruited (n = 105). All infants had Echocardiograph (ECHO; within 3 days) and blood samples drawn at the same time for B-type natriuretic peptide (BNP; part 1) and NTproBNP (N-terminal pro BNP; part 2) measurements. HsPDA was defined as a PDA diameter > 1.5 mm and BNP levels > 40 pg/mL or NTproBNP > 10,200 pg/mL. Infants were divided into two groups based on antenatal MgSO4 exposure. Data were analyzed using SPSS 23. Difference in baseline characteristics and antenatal steroid use in the two groups was analyzed. A matched group analysis was performed to adjust for the difference in the numbers between the two groups. A p-value < 0.05 was considered significant.

Results There was no significant difference seen in baseline characteristics or use of antenatal steroids in exposed versus unexposed (n = 95 vs. n = 10). There was a significant negative correlation between antenatal MgSO4 exposure and HsPDA in PI (p ≤ 0.05). However, this association was not significant after matched group analysis.

Conclusion Antenatal MgSO4 exposure is not associated with an increased risk of HsPDA. It may be associated with a decreased likelihood of HsPDA.

Keywords

neonatology - pediatric cardiology - patent ductus arteriosus - MgSO4 - NTproBNP
 

  • References

  • 1 Jacquemyn Y, Zecic A, Van Laere D, Roelens K. The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection. Arch Gynecol Obstet 2015; 291 (05) 969-975
    CrossrefPubMedGoogle Scholar
  • 2 Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995; 95 (02) 263-269
    PubMedGoogle Scholar
  • 3 Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996; 276 (22) 1805-1810
    CrossrefPubMedGoogle Scholar
  • 4 Crowther CA, Hiller JE, Doyle LW, Haslam RR. ; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290 (20) 2669-2676
    CrossrefPubMedGoogle Scholar
  • 5 Marret S, Marpeau L, Zupan-Simunek V. , et al; PREMAG trial group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007; 114 (03) 310-318
    PubMedGoogle Scholar
  • 6 Rouse DJ, Hirtz DG, Thom E. , et al; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359 (09) 895-905
    CrossrefPubMedGoogle Scholar
  • 7 Dice JE, Bhatia J. Patent ductus arteriosus: an overview. J Pediatr Pharmacol Ther 2007; 12 (03) 138-146
    PubMedGoogle Scholar
  • 8 Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr 2015; 169 (09) 863-872
    CrossrefPubMedGoogle Scholar
  • 9 Weisz DE, McNamara PJ, El-Khuffash A. Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. Early Hum Dev 2017; 105 (105) 41-47
    CrossrefPubMedGoogle Scholar
  • 10 Mancini MC, Barbosa NE, Banwart D, Silveira S, Guerpelli JL, Leone CR. Intraventricular hemorrhage in very low birth weight infants: associated risk factors and outcome in the neonatal period. Rev Hosp Clin Fac Med Sao Paulo 1999; 54 (05) 151-154
    CrossrefPubMedGoogle Scholar
  • 11 Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82 (04) 527-532
    PubMedGoogle Scholar
  • 12 Gordon P, Christensen R, Weitkamp J-H, Maheshwari A. Mapping the new world of necrotizing enterocolitis (NEC): review and opinion. EJ Neonatol Res 2012; 2 (04) 145-172
    PubMedGoogle Scholar
  • 13 Reid S, Bajuk B, Lui K, Sullivan EA. ; NSW and ACT Neonatal Intensive Care Units Audit Group, PSN. Comparing CRIB-II and SNAPPE-II as mortality predictors for very preterm infants. J Paediatr Child Health 2015; 51 (05) 524-528
    CrossrefPubMedGoogle Scholar
  • 14 James AT, Corcoran JD, Hayes B, Franklin O, El-Khuffash A. The effect of antenatal magnesium sulfate on left ventricular afterload and myocardial function measured using deformation and rotational mechanics imaging. J Perinatol 2015; 35 (11) 913-918
    CrossrefPubMedGoogle Scholar
  • 15 Paradisis M, Osborn DA, Evans N, Kluckow M. Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery-neonatal cardiovascular effects. J Perinatol 2012; 32 (09) 665-670
    CrossrefPubMedGoogle Scholar